Cryptogenic organizing pneumonitis: Difference between revisions

Jump to navigation Jump to search
Michael Maddaleni (talk | contribs)
No edit summary
Michael Maddaleni (talk | contribs)
No edit summary
Line 15: Line 15:
{{CMG}}
{{CMG}}


{{SK}} Bronchiolitis obliterans organizing pneumonia; BOOP; COP;
{{SK}} Bronchiolitis obliterans organizing pneumonia; BOOP; COP
 
==Overview==


'''Cryptogenic Organizing Pneumonitis''' (COP) or '''Bronchiolitis Obliterans Organizing Pneumonia''' (BOOP) is a rapidly developing pneumonia-like illness characterised by lung inflammation and scarring that obstruct the small airways and air sacs of the lungs (alveoli). Its name is derived from the fact that it closely mimics pneumonia infections. (The term COP is used in Europe and BOOP in North America.)  
'''Cryptogenic Organizing Pneumonitis''' (COP) or '''Bronchiolitis Obliterans Organizing Pneumonia''' (BOOP) is a rapidly developing pneumonia-like illness characterised by lung inflammation and scarring that obstruct the small airways and air sacs of the lungs (alveoli). Its name is derived from the fact that it closely mimics pneumonia infections. (The term COP is used in Europe and BOOP in North America.)  

Revision as of 14:14, 24 September 2012

Template:DiseaseDisorder infobox

WikiDoc Resources for Cryptogenic organizing pneumonitis

Articles

Most recent articles on Cryptogenic organizing pneumonitis

Most cited articles on Cryptogenic organizing pneumonitis

Review articles on Cryptogenic organizing pneumonitis

Articles on Cryptogenic organizing pneumonitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cryptogenic organizing pneumonitis

Images of Cryptogenic organizing pneumonitis

Photos of Cryptogenic organizing pneumonitis

Podcasts & MP3s on Cryptogenic organizing pneumonitis

Videos on Cryptogenic organizing pneumonitis

Evidence Based Medicine

Cochrane Collaboration on Cryptogenic organizing pneumonitis

Bandolier on Cryptogenic organizing pneumonitis

TRIP on Cryptogenic organizing pneumonitis

Clinical Trials

Ongoing Trials on Cryptogenic organizing pneumonitis at Clinical Trials.gov

Trial results on Cryptogenic organizing pneumonitis

Clinical Trials on Cryptogenic organizing pneumonitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cryptogenic organizing pneumonitis

NICE Guidance on Cryptogenic organizing pneumonitis

NHS PRODIGY Guidance

FDA on Cryptogenic organizing pneumonitis

CDC on Cryptogenic organizing pneumonitis

Books

Books on Cryptogenic organizing pneumonitis

News

Cryptogenic organizing pneumonitis in the news

Be alerted to news on Cryptogenic organizing pneumonitis

News trends on Cryptogenic organizing pneumonitis

Commentary

Blogs on Cryptogenic organizing pneumonitis

Definitions

Definitions of Cryptogenic organizing pneumonitis

Patient Resources / Community

Patient resources on Cryptogenic organizing pneumonitis

Discussion groups on Cryptogenic organizing pneumonitis

Patient Handouts on Cryptogenic organizing pneumonitis

Directions to Hospitals Treating Cryptogenic organizing pneumonitis

Risk calculators and risk factors for Cryptogenic organizing pneumonitis

Healthcare Provider Resources

Symptoms of Cryptogenic organizing pneumonitis

Causes & Risk Factors for Cryptogenic organizing pneumonitis

Diagnostic studies for Cryptogenic organizing pneumonitis

Treatment of Cryptogenic organizing pneumonitis

Continuing Medical Education (CME)

CME Programs on Cryptogenic organizing pneumonitis

International

Cryptogenic organizing pneumonitis en Espanol

Cryptogenic organizing pneumonitis en Francais

Business

Cryptogenic organizing pneumonitis in the Marketplace

Patents on Cryptogenic organizing pneumonitis

Experimental / Informatics

List of terms related to Cryptogenic organizing pneumonitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Bronchiolitis obliterans organizing pneumonia; BOOP; COP

Overview

Cryptogenic Organizing Pneumonitis (COP) or Bronchiolitis Obliterans Organizing Pneumonia (BOOP) is a rapidly developing pneumonia-like illness characterised by lung inflammation and scarring that obstruct the small airways and air sacs of the lungs (alveoli). Its name is derived from the fact that it closely mimics pneumonia infections. (The term COP is used in Europe and BOOP in North America.)

Epidemiology

Reported incidence is 0.01%, but COP may be more common and underdiagnosed. It usually begins between the ages of 40 and 60 and affects men and women equally. The mortality rate is approximately 7%, although these tend to be the elderly or those in poor health from other conditions.

Etiology

COP/BOOP may be triggered by infections from bacteria, viruses and parasites, drugs, or toxic fumes. It was identified in 1985, although its symptoms had been noted before but not recognised as a separate lung disease.

Diagnosis

Almost 75% of people have symptoms for less than two months before seeking medical attention. A flu-like illness, with a cough, fever, a feeling of illness (malaise), fatigue, and weight loss heralds the onset in about 40% of patients. Doctors do not find any specific abnormalities on routine laboratory tests or on a physical examination, except for the frequent presence of crackling sounds (called Velcro crackles, they are "drier" and higher pitched than traditional rales) on auscultation. Pulmonary function tests usually show that the amount of air the lungs can hold is below normal. Hypoxemia at rest which is exacerbated with exercise may be present.

The chest x-ray is distinctive with features that appear similar to an extensive pneumonia, with both lungs showing widespread white patches. The white patches may seem to migrate from one area of the lung to another as the disease persists or progresses. Computed Tomography (CT) may be used to confirm the diagnosis. Bronchoscopic lung biopsy can confirm the diagnosis. In some patients, additional tissue may be required and may be obtained surgically.

Treatment

About two thirds of patients recover with corticosteroid therapy. Prednisolone is often administered in Europe and Prednisone in the USA. These two compounds differ by only one functional group and have the same clinical effect. The steroid is initially administered at high doses, typically 50 mg per day tapering down to zero over a 6 month to one year period. If the steroid treatment is halted too quickly the disease may return.

References

The Merck Manual of Medical Information - Online Edition



Template:WikiDoc Sources